Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Evotec Se (EVO)

Evotec Se (EVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,709,840
  • Shares Outstanding, K 354,371
  • Annual Sales, $ 791,730 K
  • Annual Income, $ -185,070 K
  • 60-Month Beta 1.47
  • Price/Sales 1.94
  • Price/Cash Flow N/A
  • Price/Book 1.41
Trade EVO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.06
  • Number of Estimates 3
  • High Estimate -0.03
  • Low Estimate -0.11
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.48 +1.78%
on 06/13/24
5.68 -19.72%
on 05/15/24
-0.79 (-14.77%)
since 05/13/24
3-Month
4.48 +1.78%
on 06/13/24
7.98 -42.86%
on 04/08/24
-2.51 (-35.50%)
since 03/13/24
52-Week
4.48 +1.78%
on 06/13/24
13.49 -66.20%
on 07/25/23
-7.62 (-62.56%)
since 06/13/23

Most Recent Stories

More News
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced today that Leesa Gentry has joined the Company...

RNXT : 1.0500 (-10.26%)
EVO : 4.56 (-5.49%)
Stocks Climb Before the Open as Investors Weigh Economic Outlook, U.S. JOLTs Report in Focus

June S&P 500 futures (ESM23) are up +0.29%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.61% this morning after three major U.S. benchmark indices finished the regular session mixed as weaker-than-expected...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
TSLA : 182.47 (+2.92%)
VORB : 0.0769 (-34.83%)
OKYO.LN : 1.400 (-24.32%)
BFLY : 0.9223 (-4.75%)
AMC : 5.20 (+5.91%)
ONCT : 8.30 (+0.13%)
EVO : 4.56 (-5.49%)
HLN : 8.48 (+1.92%)
CRBG : 29.01 (-0.10%)
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen

Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded LAB150,...

EVO : 4.56 (-5.49%)
Adapsyn Bioscience enters into strategic collaboration with Evotec

/CNW/ - Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced a strategic collaboration...

EVO : 4.56 (-5.49%)
Adapsyn Bioscience enters into strategic collaboration with Evotec

/PRNewswire/ - Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced a strategic...

EVO : 4.56 (-5.49%)
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced that Evotec’s Seattle-based subsidiary, Just –...

EVO : 4.56 (-5.49%)
ALPN : 64.97 (+0.02%)
Evotec SE Reports Results of Annual General Meeting 2022

HAMBURG, GERMANY / ACCESSWIRE / June 22, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its shareholders approved all proposals the Company's...

EVO : 4.56 (-5.49%)
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J

Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.

JNJ : 145.45 (+0.03%)
GLMD : 0.3600 (unch)
EVO : 4.56 (-5.49%)
EXAI : 4.76 (-6.11%)
Evotec Enters a Drug Discovery Collaboration with Janssen

HAMBURG, GERMANY / ACCESSWIRE / June 14, 2022 / Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the Company has entered a drug discovery collaboration with Janssen...

EVOTF : 9.8500 (-3.24%)
EVT : 23.15 (-0.69%)
EVO : 4.56 (-5.49%)
Evotec Adds Cell Therapy Manufacturing Facility with Acquisition of Rigenerand

CELLS PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC CELL THERAPY DISCOVERY WITH DEVELOPMENT AND MANUFACTURING

EVO : 4.56 (-5.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of...

See More

Key Turning Points

3rd Resistance Point 4.82
2nd Resistance Point 4.73
1st Resistance Point 4.65
Last Price 4.56
1st Support Level 4.48
2nd Support Level 4.39
3rd Support Level 4.31

See More

52-Week High 13.49
Fibonacci 61.8% 10.05
Fibonacci 50% 8.99
Fibonacci 38.2% 7.92
Last Price 4.56
52-Week Low 4.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar